The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Aim: To evaluate if additional cord blood transfusion could accelerate the hematopoietic
reconstitution in severe aplastic anemia(SAA) patients receiving immunosuppressive therapy
(IST).
Study design: open-labed, prospective, multicenter, randomized control study Number of
subjects: 60 each group
Treatment:
IST group: ATG (Thymoglobuline®, Genzyme) 3.5mg/kg/d×5d plus oral cyclosporine A (CSA) Cord
blood transfusion group: In addition to the same dose and course of ATG and CSA , one unit of
cord blood having no more than 2 HLA-A, B or DRB1 mismatches is transfused 24h after last
dose of ATG administration.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators:
Ruijin Hospital Shanghai Tongji Hospital, Tongji University School of Medicine Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Zhejiang Provincial Hospital of TCM